Use of pirfenidone in pediatric patients with interstitial lung disease and pulmonary fibrosis

Pediatric PulmonologyEarly View CLINICAL CORRESPONDENCE Use of pirfenidone in pediatric patients with interstitial lung disease and pulmonary fibrosis Cameron J. McKinzie PharmD, BCPPS, BCPS, CPP, Corresponding Author Cameron J. McKinzie PharmD, BCPPS, BCPS, CPP [email protected] orcid.org/0000-0003-1401-5628 Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA Department of Pediatrics, Program for Rare and Interstitial Lung Disease, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Correspondence Cameron J. McKinzie, PharmD, BCPPS, BCPS, CPP, 101 Manning Drive, CB# 7600, Chapel Hill, NC 27599, USA. Email: [email protected] Contribution: Conceptualization, Writing - original draft, Writing - review & editing, ​InvestigationSearch for more papers by this authorW. Adam Gower MD, MS, W. Adam Gower MD, MS orcid.org/0000-0001-5863-7379 Department of Pediatrics, Program for Rare and Interstitial Lung Disease, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Contribution: Conceptualization, ​Investigation, Writing - original draft, Writing - review & editingSearch for more papers by this authorJames S. Hagood MD, James S. Hagood MD orcid.org/0000-0003-3938-0330 Department of Pediatrics, Program for Rare and Interstitial Lung Disease, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Contribution: Conceptualization, Writing - original draft, ​Investigation, Writing - review & editingSearch for more papers by this authorTimothy J. Vece MD, Timothy J. Vece MD Department of Pediatrics, Program for Rare and Interstitial Lung Disease, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Contribution: Conceptualization, ​Investigation, Writing - original draft, Writing - review & editingSearch for more papers by this author Cameron J. McKinzie PharmD, BCPPS, BCPS, CPP, Corresponding Author Cameron J. McKinzie PharmD, BCPPS, BCPS, CPP [email protected] orcid.org/0000-0003-1401-5628 Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA Department of Pediatrics, Program for Rare and Interstitial Lung Disease, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Correspondence Cameron J. McKinzie, PharmD, BCPPS, BCPS, CPP, 101 Manning Drive, CB# 7600, Chapel Hill, NC 27599, USA. Email: [email protected] Contribution: Conceptualization, Writing - original draft, Writing - review & editing, ​InvestigationSearch for more papers by this authorW. Adam Gower MD, MS, W. Adam Gower MD, MS orcid.org/0000-0001-5863-7379 Department of Pediatrics, Program for Rare and Interstitial Lung Disease, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Contribution: Conceptualization, ​Investigation, Writing - original draft, Writing - review & editingSearch for more papers by this authorJames S. Hagood MD, James S. Hagood MD orcid.org/0000-0003-3938-0330 Department of Pediatrics, Program for Rare and Interstitial Lung Disease, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Contribution: Conceptualization, Writing - original draft, ​Investigation, Writing - review & editingSearch for more papers by this authorTimothy J. Vece MD, Timothy J. Vece MD Department of Pediatrics, Program for Rare and Interstitial Lung Disease, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Contribution: Conceptualization, ​Investigation, Writing - original draft, Writing - review & editingSearch for more papers by this author First published: 10 May 2023 https://doi.org/10.1002/ppul.26465Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1Deterding R, Young LR, DeBoer EM, et al. Nintedanib in children and adolescents with fibrosing interstitial lung diseases. Eur Respir J. 2023; 61(2):2201512. doi:10.1183/13993003.01512-2022 2Bradford L, Ross MK, Minso J, et al. Interstitial lung disease in children with Rubinstein-Taybi syndrome. Pediatr Pulmonol. 2022; 57(1): 264- 272. 3Deng L, Chen Y, Hu X, Zhou J, Zhang Y. Case report: successful treatment of refractory interstitial lung disease with Cyclosporine A and Pirfenidone in a child with SLE. Front Immunol. 2021; 12:708463. doi:10.3389/fimmu.2021.708463 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation